Section Arrow
NMRA.NASDAQ
- Neumora Therapeutics
Quotes are at least 15-min delayed:2026/04/22 07:26 EDT
Pre Market
Last
 2.39
+0.07 (+3.02%)
Bid
2.32
Ask
2.4
High 2.4635 
Low 2.32 
Volume 34.61K 
Regular Hours (Closed)
Last
 2.32
+0.13 (+5.94%)
Day High 
2.41 
Prev. Close
2.19 
1-M High
2.6272 
Volume 
1.89M 
Bid
2.32
Ask
2.4
Day Low
2.09 
Open
2.2 
1-M Low
1.82 
Market Cap 
398.67M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.09 
20-SMA 2.16 
50-SMA 2.73 
52-W High 3.65 
52-W Low 0.611 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.45/-1.08
Enterprise Value
453.39M
Balance Sheet
Book Value Per Share
0.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
Pre Market 0.2225 +0.0257 +13.06%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
Pre Market 2.51 -0.18 -6.69%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
Pre Market 0.3134 -0.0253 -7.47%
GERNGeron Corp1.5-0.06-3.85%-- 
Pre Market 1.52 +0.02 +1.33%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Pre Market 5.47 -0.52 -8.68%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.